TNXP7:00 AMTonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®tonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officertonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conferencetonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational HighlightsTrial Start • Phase 2Trial initiation Mon, Jun 1, 2026, 7:00 AM EDTGtonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.tonixpharma.com
TNXP7:00 AMTonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026tonixpharma.com
TNXP9:05 AMTonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Modelstonixpharma.com